Synchron cx5 analyzer system

We included 968 unrelated adult Mexican Mestizos belonging to the DMS1 SIGMA-cohort [14 (link)] who were previously sequenced by Sure-Select Human All Exon v2.0 (Illumina) and included in the ExAC project [4 (link)]. A peripheral blood sample was collected after fasting for at least 8 h. The following clinical and biochemical data were obtained for all participants of the DMS1 cohort using the Synchron CX5 Analyzer System (Beckman Coulter Fullerton, CA, USA): FG (mg/dL), HDL (mg/dL), and serum triglycerides (mg/dL). HbA1c levels were measured using the IN2it analyzer (Bio-Rad, Hercules, CA, USA). Blood pressure was measured using a digital blood pressure monitor (HEM-907XL, OMRON). Weight and height were measured using a body composition monitor (HBF-500 INT, OMRON) and electronic stadiometer (ADE Germany). Waist circumference was measured midway between the inferior margin of the ribs and the border of the iliac crest using a flexible clinical measuring tape.
The study was carried out according to the Declaration of Helsinki and was approved by the Research, Ethics, and Biosafety Human Committees of the Instituto Nacional de Medicina Genómica (INMEGEN) in Mexico City. All participants provided written informed consent. They were recruited from August 2017 to December 2018, all of them inhabited the Valley of Mexico.

Levels of triglycerides (TG), total cholesterol (TC), and HDL-C were measured from blood samples collected after overnight fasting, using a Synchron CX5 Analyzer System (Beckman Coulter Fullerton, CA, United States). LDL-C values were calculated with the Friedewald formula, excluding those samples with TG > 400 mg/dl (Warnick et al., 1990 (link)).
Each lipid disorder was diagnosed according to the American Heart Association and National Heart, Lung, and Blood Institute guidelines (AHA/NHLBI; http://www.nhlbi.nih.gov). An individual was diagnosed with a lipid disorder when serum levels showed any of the following: TG ≥ 150 mg/dl (hypertriglyceridemia; HTG), TC ≥ 200 mg/dl (hypercholesterolemia; HTC), LDL-C ≥130 mg/dl (elevated LDL), or HDL-C ≤50 mg/dl in females or ≤40 mg/dl in males (low HDL-C). Individuals with desirable lipid values were assigned as controls. Data on lipid-lowering medications were available for over 80% of the participants and adjustment was done for TG and TC binary phenotypes.